Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study

Collins, Barbara; MacKenzie, Joyce; Stewart, A.; Bielajew, Catherine; Verma, Shailendra

doi:10.1002/pon.1453

Cited by 132 publications

(154 citation statements)

References 53 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Poorer performance on the AVLT learning delay test predicted difficulty meeting the mental and interpersonal demands of work. As other studies have shown, 33,34 reports of greater number of depressive symptoms were highly correlated with difficulties meeting the time management, physical, and mental/interpersonal demands of work as well as the overall percent of healthrelated work productivity loss.…”

Section: Discussionsupporting

confidence: 56%

Cognitive and Occupational Function in Survivors of Adolescent Cancer

Nugent

Bender

Sereika

et al. 2018

Journal of Adolescent and Young Adult Oncology

View full text Add to dashboard Cite

The number of cancer survivors living in the U.S. is dramatically increasing. Cognitive decline is a commonly reported and burdensome symptom of cancer survivors. In addition, many cancer survivors experience difficulty maintaining employment. This dissertation addresses gaps in the literature of cognitive and occupational function of cancer survivors, with particular emphasis on the understudied population of cancer survivors diagnosed as an adolescent or young adult (AYA). For this dissertation, a series of studies were conducted to 1) explore the association between occupation and symptom burden in breast cancer survivors, 2) synthesize the evidence of cognitive outcomes in survivors of AYA cancer, and 3) describe cognitive and occupational function in survivors of adolescent cancer compared to healthy controls.To address aim one, a secondary analysis of data from early-stage breast cancer survivors explored the relationship between occupation and symptom burden. Breast cancer survivors employed in lower skill level jobs reported greater symptom burden over the first year of anastrozole treatment than women employed at the higher skill level. Survivors employed at lower skill levels had higher levels of fatigue and worse depressive, musculoskeletal, vasomotor, and gastrointestinal symptoms.To address aim two, an integrative review synthesized the current state of science in terms of cognitive outcomes of those diagnosed with cancer as an AYA. Survivors of AYA cancer tended to experience cognitive difficulties; however, to date, no study has focused exclusively on those diagnosed as an AYA or encompassed the entirety of the AYA age range. Future iv studies are needed because cognitive outcomes of survivors of AYA cancer have been largely neglected.Lastly, a cross-sectional, descriptive comparative study described cognitive and occupational function in survivors of adolescent cancer compared to healthy controls. Survivors of adolescent cancer perceived greater cognitive difficulty than healthy peers, although there were not significant measurable differences in performance on neuropsychological tests. Survivors of adolescent cancer also reported poorer work output than healthy controls.This dissertation contributes to the growing body of literature pertaining to health and well-being of cancer survivors, in particular cognitive and occupational function, and unique considerations needed for those diagnosed with cancer as an AYA.v Study 2. While there is a growing body of literature suggesting that many cancer survivors may experience cognitive decline after cancer diagnosis and treatment, much less is known about the cognitive outcomes of those diagnosed during the AYA timeframe. Therefore, the second study of this dissertation is an integrative review to summarize and appraise the current state of published literature involving cognitive function in those diagnosed during adolescence and young adulthood. While the review is a distinct study within the dissertation project, it provides a critically important ...

show abstract

Section: Discussionsupporting

confidence: 56%

Cognitive and Occupational Function in Survivors of Adolescent Cancer

Nugent

Bender

Sereika

et al. 2018

Journal of Adolescent and Young Adult Oncology

View full text Add to dashboard Cite

show abstract

“…Accordingly, adjuvant endocrine therapy in postmenopausal breast cancer may influence cognitive function. Tamoxifen was negatively associated with cognitive functions in some reports (Paganini-Hill & Clark 2000, Collins et al 2009) and the TEAM trial confirmed these findings by showing that tamoxifen is significantly associated with lower functioning in verbal memory and executive functioning (Schilder et al 2010). Exemestane, on the other hand, did not show significantly worse outcomes for any cognitive domain compared with healthy controls.…”

Section: Cognitionsupporting

confidence: 63%

Aromatase inhibitors in the breast cancer clinic: focus on exemestane

Asten¹,

Neven²,

Lintermans³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most prevalent type of cancer in women and responsible for significant female cancer-related mortality worldwide. In the Western world, over 80% of breast cancers are hormone-receptor positive for which endocrine therapy is administered. The main anti-estrogen treatments in use consist of selective estrogen-receptor modulators, such as tamoxifen, and third-generation aromatase inhibitors (AIs), such as exemestane, letrozole, and anastrozole. In this review, the focus will lie on exemestane, its clinical use, and its side-effect profile. Exemestane is the only third-generation steroidal AI. Its efficacy as a first-line treatment in metastatic breast cancer has been demonstrated. Therefore, exemestane could be considered a valid first-line therapeutic option, but it also can be used in second-line or further situations. Exemestane is mostly used as part of sequential adjuvant treatment following tamoxifen, but in this setting it is also active in monotherapy. Furthermore, this AI has been studied in the neoadjuvant setting as presurgical treatment, and even as chemoprevention in high-risk healthy postmenopausal women. It may reverse side effects of tamoxifen, such as endometrial changes and thromboembolic disease but may also cause some inconvenient side effects itself. Additionally, there is a lack of total crossresistance between exemestane and nonsteroidal AIs as far as their anti-tumoral efficacy is concerned; moreover the two classes of AIs display a nontotal overlapping toxicity profile. Taking together, exemestane can be considered as a useful treatment option at all stages of breast cancer.

show abstract

“…Most of the participants in the present study showed no depression or anxiety. Moreover, the cognitive decline was not found among the patients who went into menopause or used some hormonal therapy, although menopausal status and hormone therapy might affect the cognitive function (38). These may have been related to the fact that the neuropsychological test results did not detect cognitive decline.…”

Section: Discussionmentioning

confidence: 93%

Potential Role of pNF-H, a Biomarker of Axonal Damage in the Central Nervous System, as a Predictive Marker of Chemotherapy-Induced Cognitive Impairment

Natori

Ogata

Sumitani

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Chemotherapy-induced cognitive impairment (CICI) is a clinically significant problem. Previous studies using magnetic resonance imaging indicated structural changes in the cerebral white matter of patients with CICI. Phosphorylated neurofilament heavy subunit (pNF-H), a major structural protein in axons, was recently reported to be elevated in the serum of patients with some central nervous system disorders. We performed a cross-sectional analysis of neuropsychological test results and serum pNF-H levels in patients undergoing adjuvant chemotherapy for breast cancer. Our hypothesis was that CICI is accompanied by axonal damage that can be detected by elevated serum pNF-H levels. Experimental Design: Seventy-six patients with early breast cancer in various phases of treatment (naïve to chemotherapy; after one, three, or seven cycles of chemotherapy; or with a history of chemotherapy) were assessed by self-administered neuropsychological tests and a single pNF-H measurement. The χ2 and Mann–Whitney tests were used for statistical analysis. Results: Increased pNF-H levels were observed in 28.8% of the patients who underwent chemotherapy, but in none of the chemotherapy-naïve patients or patients with a history of chemotherapy. The pNF-H–positive rate increased significantly in proportion to the number of chemotherapy cycles (one cycle, 5.0%; three cycles, 31.6%; seven cycles, 55.0%; P < 0.05). No significant differences in neuropsychological test results were observed among the groups. Conclusions: The serum pNF-H level in patients undergoing chemotherapy for breast cancer increased in a cumulative dose-dependent manner, suggesting its potential application as a biomarker of neural damage after chemotherapy. Clin Cancer Res; 21(6); 1348–52. ©2015 AACR.

show abstract

Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study

Cited by 132 publications

References 53 publications

Cognitive and Occupational Function in Survivors of Adolescent Cancer

Cognitive and Occupational Function in Survivors of Adolescent Cancer

Aromatase inhibitors in the breast cancer clinic: focus on exemestane

Potential Role of pNF-H, a Biomarker of Axonal Damage in the Central Nervous System, as a Predictive Marker of Chemotherapy-Induced Cognitive Impairment

Contact Info

Product

Resources

About